β-amyloid deposition highly variable in

β-amyloid deposition highly variable in
synucleinopathy
By Eleanor McDermid, Senior medwireNews Reporter
Mov Disord 2015; Advance online publication
medwireNews: A meta-analysis suggests
The researchers suggest the diﬀerent rates
large variability in the prevalence of β-amyloid
between the two groups may be partly
deposition in patients with synucleinopathies.
explained by classiﬁcation bias. Most patients
w i th a h i g h β- am y l o i d b u r d e n a s w e l l a s
The research team analysed 11 studies,
synucleinopathy will present with dementia or
which included 74 patients diagnosed with
develop it very quickly and therefore be
Parkinson’s disease (PD) with dementia, 99
classiﬁed as DLB, whereas parkinsonism
with dementia with Lewy bodies (DLB) and 60
symptoms will predominate in patients with a
with PD and mild cognitive impairment (MCI).
lower β-amyloid burden, leading to a diagnosis
of PD with dementia.
Myria Petrou (University of Michigan, Ann
Arbor, USA) and study co-authors note that β
By contrast, the prevalence of β-amyloid
-amyloid deposition is rarely studied in such
positivity was very low among PD patients
patients, despite the high prevalence of
with MCI, at just 0.05, and there was no
dementia and the important role of β-amyloid
evidence of study heterogeneity.
in conditions such as Alzheimer’
s.
The team notes that the pooled prevalence of
“Therefore, our systematic review of the
β-amyloid deposition in the PD patients with
existing, smaller studies in this setting is
MCI is lower than that reported in otherwise
pertinent”, they write in Movement Disorders.
healthy people with MCI and is even slightly
lower than that found in cognitively normal
The pooled prevalence of β-amyloid‒positivity
elderly people, although not signiﬁcantly so.
was highest among patients with DLB, at
0.68. The next highest prevalence was among
This provides an interesting direction for
PD patients with dementia, at 0.34.
future research, they say,“because
Heterogeneity was more than 70% among
conﬁrmation of lower cortical amyloid
these studies.
deposition in these populations may… provide
clues into the modulation of amyloid precursor
protein metabolism and deposition in vivo.”
Medwire Newsは、Springer Healthcareが運営している医療業界者向けの独立性の高いニュースサイトです。2000年からサービスを開始し、注目すべきニュースを1日平均20本配信してい
ます。Medwire News編集部では、国際的に認知されているジャーナル(学術誌)の論文、国際学会の速報、医療基礎研究の報告を情報ソースとしています。
これらのニュースは、急速に発展を
する医療開発や臨床試験の現場に向けて最新の研究結果をお伝えすることを目的に、経験豊かなメディカル・エディターによって最新かつ信頼できるニュースを配信しています。
掲載されたニュースには海外で実施された試験が含まれており、本邦で承認されている効能・効果および用法・用量とは異なる場合があります。掲載の情報は第3者機関により提供されており、
情報
確性、通用性、完全性
て
グラクソ・スミスクライン株式会社が内容について関与するものではありません。
日本語レビューの精度については細心の注意を払っておりますが、
その情報の正確性、
完全性について
は、
いかなる責任を負うものではなく、保証するものではありません。

Download Report